Buyout + special sits fund research profile
PAG is an Asia-focused alternative manager with private equity, real assets and credit businesses. Its India private-equity activity is led by Nikhil Srivastava and is visible through Nuvama, healthcare and pharmaceutical positions, alongside a broader multi-asset platform.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
PAG (India) uses a buyout + special sits approach across Consumer, health, RE.
Current evidence
PAG’s current private-equity page identifies Nuvama Wealth Management and Acme Formulation as India investments. PAG’s 2025 company profile reports more than $55 billion of assets under management and identifies Nikhil Srivastava as a senior investor who has worked across India, Singapore and the US; India-only book size and returns are not publicly disclosed.
Strategy
Buyout + special sits
Sector focus
Consumer, health, RE
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
PAG’s current private-equity page identifies Nuvama Wealth Management and Acme Formulation as India investments. PAG’s 2025 company profile reports more than $55 billion of assets under management and identifies Nikhil Srivastava as a senior investor who has worked across India, Singapore and the US; India-only book size and returns are not publicly disclosed.
Investor questions
PAG (India) is covered in Rupeia's private equity research universe. The current public record describes the strategy as Buyout + special sits, with a sector focus of Consumer, health, RE. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to PAG (India) in the reviewed public sources: Nuvama Wealth Management, Acme Formulation. It does not represent a complete current portfolio unless the manager has published one.
PAG’s India record includes the Edelweiss Wealth carve-out that became Nuvama, plus Acme Formulation and Sekhmet Pharma Ventures positions. Public sources reviewed do not disclose India fund-level IRR or DPI. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: PAG reports more than $60B AUM as of June 30, 2026, including $21B private equity, $14B real assets and $25B credit and markets; India-only AUM is not separately disclosed.. Public terms or access information: Large-scale control buyouts and structured minority investments across Asia, alongside special situations and credit. India cheque sizes and reserve policy are not consistently disclosed.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Nikhil Srivastava (India PE head). Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: PAG does not publicly disclose India-only AUM, fund-level returns or complete transaction terms for the India private-equity positions..
2025-12-31: PAG’s current private-equity page identifies Nuvama Wealth Management and Acme Formulation as India investments. PAG’s 2025 company profile reports more than $55 billion of assets under management and identifies Nikhil Srivastava as a senior investor who has worked across India, Singapore and the US; India-only book size and returns are not publicly disclosed.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.